Distribution of ?-Glutamyl Transferase in Some Domestic Animals

2015 ◽  
pp. 46-49 ◽  
Author(s):  
J. P. Braun ◽  
A. G. Rico ◽  
P. Benard ◽  
V. Burgat
Keyword(s):  
Domestic Animals ◽  
Glutamyl Transferase

Gamma Glutamyl Transferase in domestic animals

1983 ◽  
Vol 6 (1) ◽  
pp. 77-90 ◽  
Author(s):  
J. P. Braun ◽  
P. Benard ◽  
V. Burgat ◽  
A. G. Rico
Keyword(s):  
Domestic Animals ◽  
Gamma Glutamyl Transferase ◽  
Gamma Glutamyl ◽  
Glutamyl Transferase

Referenzwerte blutchemischer Parameter bei Meerschweinchen bestimmt mit dem Vettest® 8008

2011 ◽  
Vol 39 (03) ◽  
pp. 170-175 ◽  
Author(s):  
H. Rabe
Keyword(s):  
Alkalische Phosphatase ◽  
Glutamyl Transferase

Zusammenfassung Gegenstand: Die Studie präsentiert Referenzbereiche für ein praxisübliches Trockenchemiegerät (Vettest® 8008), die bei als Heimtiere gehaltenen Meerschweinchen ermittelt wurden. Material und Methoden: Bei den Probanden handelte es sich um 58 klinisch gesunde Meerschweinchen im Alter zwischen 8 Wochen und 5 Jahren (24 männlich, 34 weiblich). Die Plasmaproben wurden routinemäßig für die Untersuchung im Vettest® 8008 aufgearbeitet und auf 20 Parameter (s. u.) untersucht. Zur Ermittlung der Referenzwerte wurden mittels SPSS Statistics 17.0 (IBM®) die 2,5%- und 97,5%-Perzentile bestimmt. Ergebnisse: Folgende Referenzwerte wurden ermittelt: 1) Enzyme: alkalische Phosphatase: 50,80–328,10 U/l; Alaninaminotransferase: 41,45 bis 165,35 U/l; Amylase: 726,93–1831,55 U/l; Aspartataminotransferase: 25,25–349,23 U/l; Kreatinkinase: 66,13–1255,40 U/l, γ-Glutamyl- Transferase: 0,45–90,75 U/l; Laktatdehydrogenase: 5,61–1503,00 U/l, Lipase: keine messbare Aktivität. 2) Substrate: Albumin: 17,45 bis 31,65 g/l; Ammoniak: 4,80–225,30 mmol/l; Cholesterin: 0,0 bis 2,06 mmol/l; Kreatinin: 23,90–73,45 μmol/l; Gesamtbilirubin: 2,00 bis 17,60 μmol/l; Gesamteiweiß: 50,00–70,85 g/l; Glukose: 4,62 bis 19,55 mmol/l; Harnstoff-Stickstoff: 2,04–11,28 mmol/l; Triglyzeride: 0,46–4,23 mmol/l. Die Globuline wurden vom Gerät rechnerisch ermittelt: 30,43–42,00 g/l. 3) Elektrolyte: anorganisches Phosphat: 0,72 bis 2,12 mmol/l, Kalzium: 2,58–3,16 mmol/l; Magnesium: 0,72 bis 1,60 mmol/l. Schlussfolgerungen: Der Vergleich mit Angaben aus der Literatur zeigt Abweichungen der Studien untereinander und von der vorliegenden Arbeit. Daraus ist die Schlussfolgerung zu ziehen, dass Referenzwerte unterschiedlicher Untersuchungsverfahren nicht unkritisch für das tierärztliche Sofortlabor übernommen werden können und zur Interpretation von Blutbefunden eigene Referenzwerte für die einzelnen Gerätetypen notwendig sind. Mögliche Ursachen für die Abweichungen könnten in unentdeckten subklinischen Erkrankungen sowie chemischer oder statistischer Methodik liegen.

Relation between Plasminogen Activator Inhibitor-1 and Hepatic Enzyme Concentrations in Hyperlipidemic Patients

1994 ◽  
Vol 72 (03) ◽  
pp. 434-437 ◽  
Author(s):  
E Bruckert ◽  
A Ankri ◽  
P Glral ◽  
G Turpin
Keyword(s):  
Blood Pressure ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Tolerance Test ◽  
High Plasma ◽  
Oral Glucose ◽  
Plasminogen Activator Inhibitor 1 ◽  
Glutamyl Transferase ◽  
Activator Inhibitor ◽  
Pai 1

SummaryPlasminogen activator inhibitor type-1 (PAI-1) is a key determinant of the fibrinolytic capacity. Its activity correlates with most of the characteristic features of insulin resistance syndrome, i. e. obesity, high blood pressure and hyperlipidemia.We measured plasma PAI-1 antigen levels in 131 asymptomatic men (aged 44.2 ± 11 years) who had been referred for hyperlipidemia. Those taking medication and those with a secondary hyperlipidemia were excluded.We confirmed the correlation between PAI-1 levels and the following variables: body mass index, blood pressure, triglyceride concentration, and blood glucose and insulin levels before and after an oral glucose tolerance test. We also found a significant and independent correlation between PAI-1 and the concentration of the hepatic enzymes glutamyl transferase, alanine aminotransferase and aspartate aminotransferase.Mild liver abnormalities (presumably steatosis) may thus be one of the factors accounting for high plasma PAI-1 levels in hyperlipidemic patients.

PROBLEMS OF STRAY ANIMALS IN NOVOSIBIRSK

2020 ◽  
Vol 4 (2) ◽  
pp. 85-91
Author(s):  
Elena E. Rinchinova ◽  
Diyara A. Takumova ◽  
Irina I. Bochkareva
Keyword(s):  
Urban Population ◽  
Domestic Animals ◽  
Legal Documents ◽  
Quantitative Indicators ◽  
The City

The article discusses main issues of organizing activities for the treatment of stray and street animals in the city of Novosibirsk. The important role of successful solving the problem of stray animals in ensuring environmental comfort and safety of the urban population is noted. Definitions of the concepts “stray animals” and “street animals” are given, the differences between them are emphasized. The main regulatory and legal documents governing the handling of stray and street animals are listed. The ways in which domestic animals get into a stray state are described briefly. The results of the collection and analysis of information on the activities of shelters for stray animals in Novosibirsk are described. The information on the quantitative indicators of the shelters are given. Conclusions on how to solve the problem of stray animals, relying on the latest regulations are drawn.

Recovery from LCDD-associated Severe Liver Cholestasis: a Case Report and Literature Review

2016 ◽  
Vol 25 (1) ◽  
pp. 99-103 ◽  
Author(s):  
Benoit Brilland ◽  
Johnny Sayegh ◽  
Anne Croue ◽  
Frank Bridoux ◽  
Jean-François Subra ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Light Chain ◽  
Intrahepatic Cholestasis ◽  
Relevant Literature ◽  
Gamma Glutamyl Transferase ◽  
Light Chain Deposition Disease ◽  
Deposition Disease ◽  
Uncommon Presentation ◽  
Light Chain Deposition ◽  
Glutamyl Transferase

Light chain deposition disease (LCDD) is a rare multisystemic disorder associated with plasma cell proliferation. It mainly affects the kidney, but liver and heart involvement may occur, sometimes mimicking the picture of systemic amyloidosis. Liver disease in LCDD is usually asymptomatic and exceptionally manifests with severe cholestatic hepatitis. We report the case of a 66-year-old female with κ-LCDD and cast nephropathy in the setting of symptomatic multiple myeloma who, after a first cycle of bortezomib-dexamethasone chemotherapy, developed severe and rapidly worsening intrahepatic cholestasis secondary to liver κ-light chain deposition. Intrahepatic cholestasis was attributed to LCDD on the basis of the liver histology and exclusion of possible diagnoses. Chemotherapy was maintained and resulted in progressive resolution of cholestasis. We report here an uncommon presentation of LCDD, with prominent liver involvement that fully recovered with bortezomib-based chemotherapy, and briefly review the relevant literature. Abbreviations: AKI: Acute kidney injury; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CMV: Cytomegalovirus; EBV: Epstein–Barr virus; GGT: gamma-glutamyl transferase; HSV: Herpes simplex virus; LC: light chain; LCDD: Light chain deposition disease; MIDD: Monoclonal immunoglobulin deposition disease; MM: Multiple myeloma.

Sign in / Sign up

Export Citation Format

Share Document